Table 2 Patients characteristics and main study results for AKT and MAPK immunohistochemistry in metastases
Mets Group (n = 37) | AKT positive (n = 23) | AKT negative (n = 14) | p value | MAPK positive (n = 20) | MAPK Negative (n = 17) | p value | |
|---|---|---|---|---|---|---|---|
Age (range) | 66 (36–80) | 67 (36–79) | 65 (38–80) | ns | 65 (40–80) | 66 (40–79) | ns |
Sex | |||||||
Males | 27 (73%) | 15 (65%) | 12 (85%) | ns | 13 (60%) | 14 (82) | ns |
Females | 10 (27%) | 8 (35%) | 2 (15%) | ns | 7 (40%) | 3 (18%) | ns |
ECOG PS | |||||||
0–1 | 28 (76%) | 17 (74%) | 11 (78%) | ns | 16 (80%) | 12 (70%) | ns |
2–3 | 9 (24%) | 6 (26%) | 3 (22%) | ns | 4 (20%) | 5 (30%) | ns |
Metastatic sites | |||||||
1 | 10 (27%) | 6 (26%) | 4 (28%) | ns | 5 (25%) | 5 (29%) | ns |
≥ 2 | 27 (73%) | 17 (74%) | 10 (72%) | ns | 15 (75%) | 12 (71%) | ns |
Previous lines of treatment | |||||||
1 | 9 (24%) | 5 (22%) | 4 (28%) | ns | 5 (25%) | 4 (23%) | ns |
≥ 2 | 28 (76%) | 18 (78%) | 10 (72%) | ns | 15 (75%) | 13 (77%) | ns |
Treatment | |||||||
mFOLFIRI + Cetuximab | 12 (32%) | 6 (26%) | 6 (43%) | ns | 7 (35%) | 5 (30%) | ns |
Irinotecan + Cetuximab | 25 (68%) | 17 (74%) | 8 (57%) | ns | 13 (65%) | 12 (70%) | ns |
Response Rate | |||||||
PR | 10 (27%) | 2 (9%) | 8 (58%) | 0.004 | 2 (10%) | 8 (47%) | 0.002 |
SD | 9 (25%) | 6 (26%) | 3 (21%) | ns | 5 (25%) | 4 (23%) | ns |
PD | 18 (48%) | 15 (65%) | 3 (21%) | 0.001 | 13 (65%) | 5 (30%) | 0.006 |
Survival | |||||||
m PFS (months) | 3.2 | 2.3 | 9.2 | <0.0001 | 2.3 | 8.6 | <0.0001 |
m OS (months) | 12.6 | 6.1 | 26.7 | <0.0001 | 7.8 | 26 | 0.0004 |